Piper Jaffray Companies restated their buy rating on shares of Becton, Dickinson and Company (NYSE:BDX) in a research note published on Tuesday. Piper Jaffray Companies currently has a $213.00 price objective on the medical instruments supplier’s stock.

BDX has been the subject of several other research reports. BidaskClub raised Becton, Dickinson and from a hold rating to a buy rating in a research report on Monday, August 14th. Cowen and Company reissued an outperform rating and issued a $230.00 target price (up previously from $200.00) on shares of Becton, Dickinson and in a research report on Monday, July 10th. Barclays PLC reissued an equal weight rating and issued a $210.00 target price (up previously from $205.00) on shares of Becton, Dickinson and in a research report on Thursday, August 10th. Zacks Investment Research raised Becton, Dickinson and from a hold rating to a buy rating and set a $225.00 target price for the company in a research report on Monday, July 17th. Finally, Raymond James Financial, Inc. raised Becton, Dickinson and from an outperform rating to a strong-buy rating and decreased their target price for the stock from $210.00 to $180.00 in a research report on Friday, June 30th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $196.93.

Shares of Becton, Dickinson and (BDX) opened at 202.20 on Tuesday. The firm has a market cap of $46.01 billion, a P/E ratio of 58.56 and a beta of 1.06. Becton, Dickinson and has a 52 week low of $161.29 and a 52 week high of $206.63. The stock has a 50 day moving average of $200.08 and a 200 day moving average of $191.02.

Becton, Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The firm had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. During the same quarter in the prior year, the company earned $2.35 EPS. The business’s revenue was down 5.1% compared to the same quarter last year. Equities analysts forecast that Becton, Dickinson and will post $9.46 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/13/becton-dickinson-and-company-bdx-receives-buy-rating-from-piper-jaffray-companies.html.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, September 8th will be paid a dividend of $0.73 per share. The ex-dividend date is Thursday, September 7th. This represents a $2.92 annualized dividend and a yield of 1.44%. Becton, Dickinson and’s dividend payout ratio is 83.43%.

In other news, insider Thomas E. Polen, Jr. sold 5,971 shares of the firm’s stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total value of $1,178,735.11. Following the transaction, the insider now directly owns 12,861 shares in the company, valued at approximately $2,538,890.01. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Ellen R. Strahlman sold 9,283 shares of the firm’s stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $198.21, for a total value of $1,839,983.43. Following the completion of the transaction, the insider now owns 26,638 shares in the company, valued at $5,279,917.98. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 75,904 shares of company stock worth $15,242,688. Company insiders own 1.40% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. North Star Investment Management Corp. boosted its stake in shares of Becton, Dickinson and by 3.4% in the 1st quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock worth $101,000 after buying an additional 18 shares during the last quarter. Almanack Investment Partners LLC. purchased a new position in shares of Becton, Dickinson and in the 1st quarter worth $105,000. Parkside Financial Bank & Trust boosted its stake in shares of Becton, Dickinson and by 1.4% in the 1st quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after buying an additional 9 shares during the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its stake in shares of Becton, Dickinson and by 55.8% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock worth $131,000 after buying an additional 240 shares during the last quarter. Finally, Harfst & Associates Inc. boosted its stake in shares of Becton, Dickinson and by 46.4% in the 2nd quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock worth $135,000 after buying an additional 221 shares during the last quarter. Hedge funds and other institutional investors own 87.43% of the company’s stock.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Analyst Recommendations for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.